SEC Form 4 · accession 0001209191-15-083748
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Andrew Smith
Officer — See Remarks
Period of report
Dec 3, 2015
Accepted (ET)
Dec 7, 2015 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 3, 2015 | M | 10,000 | $0.00 | A | 29,433 | D | |
| Common Stock | Dec 3, 2015 | F | 5,185 | $106.55 | D | 24,248 | D | |
| Common Stock | holding | — | — | — | 2,503 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F1 | — | Dec 3, 2015 | M | 10,000 | D | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1All of the restricted stock units granted to the reporting person on December 3, 2012 vested and settled for shares of the Company's common stock.
- F2The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated on April 15, 2015). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
Remarks
President Inflammation & Immunology